Patients and clinicians should understand that CAR T-cell therapy requires continuous long-term management. This includes monthly IVIG infusions for hypogammaglobulinemia and monitoring for cytopenias, contrasting with the more predictable recovery from a stem cell transplant.
Unlike stem cell transplants, CAR T-cell therapy has less intense conditioning, making it a viable option for patients into their late 80s. Eligibility focuses more on fitness and frailty rather than chronological age, broadening access for a larger patient population.
The standard of care for CRS has evolved. Instead of waiting for CRS to escalate, institutions now immediately administer dexamethasone and tocilizumab at the first sign of a fever (grade 1), finding it doesn't harm CAR T-cell expansion and improves safety.
A growing number of myeloma patients relapse biochemically, meaning their lab markers worsen while they feel perfectly fine. This presents a difficult conversation, as clinicians must convince an asymptomatic patient of the need to restart or change intensive therapy.
Bispecific antibodies are "off-the-shelf" therapies with manageable side effects that don't require specialized manufacturing centers like CAR T. This allows community practices to administer highly effective T-cell redirecting therapies, equalizing access for patients far from major academic institutions.
Unlike CAR T and bispecifics, the antibody-drug conjugate Belantamab doesn't rely on T-cell function. This makes it a strategic choice for patients who have previously received T-cell engaging therapies, allowing their T-cells to recover while still providing an effective BCMA-targeted treatment.
Clinicians are successfully managing Belantamab's primary side effect, keratopathy, by using lower starting doses and extending dosing intervals to every 8 or 12 weeks once a response is seen. This maintains efficacy while significantly improving tolerability for patients.
New oral CELMoDs like mezigdemide show a surprising ability to make previously ineffective drugs, like bortezomib and carfilzomib, work again. This resensitization mechanism offers a powerful strategy to recycle older therapies, expanding options for heavily pretreated patients.
Unlike post-transplant patients who visually appear sick, CAR T recipients often look healthy but suffer from profound, months-long fatigue. Nurses must educate patients and families about this invisible side effect to ensure they receive adequate support and don't dismiss their exhaustion.
Experts advise referring patients to CAR T centers upon diagnosis, not when they need the therapy. This isn't for a "second opinion" but to establish a collaborative relationship early. This facilitates seamless access and planning when CAR T becomes necessary later.
When introducing the overall, multi-year treatment plan at the beginning, it helps patients conceptualize myeloma as a chronic condition rather than a series of acute failures. This reframing prepares them for eventual relapse, reducing devastation and helping them see it as the next step in a long journey.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.